What should you know about ROS1-positive NSCLC?

NSCLC is a group of lung cancers defined by how the cells look and behave under pathology testing. ROS1-positive means a test identified a ROS1 alteration in the tumour. These are separate pieces of information: NSCLC describes the cancer group, while ROS1 can provide a treatment target.

The ROS1 result does not establish the stage or show whether treatment will suit every person. Imaging, tissue findings, symptoms, and general health are used to complete the picture. The care team also considers whether cancer is confined to the lung, nearby structures, or more distant sites.

Ask whether the ROS1 finding was confirmed and whether the report includes other changes that affect treatment. Targeted therapy is often a key discussion, while surgery such as a lung lobectomy may be considered when the tumour’s location and stage make an operation suitable. Stereotactic body radiotherapy may be discussed for selected localised areas.

Immunotherapy is a different treatment approach and is not chosen solely from a ROS1 label. Your oncologist will weigh the complete tumour profile, stage, previous treatment, symptoms, and likely side effects. Keep follow-up visits and report changes rather than altering treatment yourself.

Seek prompt clinical advice for increasing breathlessness, chest pain, coughing blood, persistent vomiting, confusion, a new severe headache, weakness, or a seizure. Emergency help is appropriate for severe breathing difficulty, collapse, or sudden neurological change. New or worsening hoarseness should be reported for assessment.

What does my ROS1 report show? What is my NSCLC stage? Why is targeted therapy recommended or not recommended? Could surgery or stereotactic body radiotherapy help? How will response and side effects be monitored?